Industry Research Reports

Home > Reports > Medical Care > Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 83 Pages

Report ld: 2332884

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size(US$)

M= millions and B=billions

Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.

The global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics was estimated to be worth US$ 7633.6 million in 2023 and is forecast to a readjusted size of US$ 11190 million by 2030 with a CAGR of 5.2% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics by region & country, by Type, and by Application.

The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics.

Market Segmentation

Report Metric
Details
Report Title
Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 11190 million
CAGR(2024-2030)
5.2%
Market Size Available for Years
2019-2030
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies Covered
Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, Segment by Type
Oral Therapy

Injectable Therapy
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, Segment by Application
Hospitals & Clinics

Home Settings

Ambulatory Surgical Centers (ASCs)
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Introduction
    1.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Forecast
    1.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Trends & Drivers
        1.3.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Industry Trends
        1.3.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers & Opportunity
        1.3.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges
        1.3.4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players Revenue Ranking (2023)
    2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Company (2019-2024)
    2.3 Key Companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Offered
    2.5 Key Companies Time to Begin Mass Production of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics
    2.6 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Competitive Analysis
        2.6.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Oral Therapy
        3.1.2 Injectable Therapy
    3.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type
        3.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, by Type (2019-2030)
        3.2.3 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Hospitals & Clinics
        4.1.2 Home Settings
        4.1.3 Ambulatory Surgical Centers (ASCs)
    4.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application
        4.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, by Application (2019-2030)
        4.2.3 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region
        5.1.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2019-2024)
        5.1.3 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2025-2030)
        5.1.4 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        5.2.2 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        5.3.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        5.4.2 Asia Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        5.5.2 South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        5.6.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value
    6.3 United States
        6.3.1 United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        6.3.2 United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        6.4.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        6.5.2 China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        6.6.2 Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        6.7.2 South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        6.8.2 Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019-2030
        6.9.2 India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Astellas Inc.
        7.1.1 Astellas Inc. Profile
        7.1.2 Astellas Inc. Main Business
        7.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
        7.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2019-2024)
        7.1.5 Astellas Inc. Recent Developments
    7.2 Johnson & Johnson
        7.2.1 Johnson & Johnson Profile
        7.2.2 Johnson & Johnson Main Business
        7.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
        7.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2019-2024)
        7.2.5 Johnson & Johnson Recent Developments
    7.3 Sanofi S.A
        7.3.1 Sanofi S.A Profile
        7.3.2 Sanofi S.A Main Business
        7.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
        7.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2019-2024)
        7.3.5 Dendreon Corporation Recent Developments
    7.4 Dendreon Corporation
        7.4.1 Dendreon Corporation Profile
        7.4.2 Dendreon Corporation Main Business
        7.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
        7.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2019-2024)
        7.4.5 Dendreon Corporation Recent Developments
    7.5 Bayer AG
        7.5.1 Bayer AG Profile
        7.5.2 Bayer AG Main Business
        7.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
        7.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2019-2024)
        7.5.5 Bayer AG Recent Developments

 8 Industry Chain Analysis
    8.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Industrial Chain
    8.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Model
        8.5.2 Sales Channel
        8.5.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Trends
    Table 2. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers & Opportunity
    Table 3. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges
    Table 4. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints
    Table 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Type
    Table 9. Key Companies Time to Begin Mass Production of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics
    Table 10. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2019-2024) & (%)
    Table 27. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2025-2030) & (US$ Million)
    Table 31. Astellas Inc. Basic Information List
    Table 32. Astellas Inc. Description and Business Overview
    Table 33. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Astellas Inc. (2019-2024)
    Table 35. Astellas Inc. Recent Developments
    Table 36. Johnson & Johnson Basic Information List
    Table 37. Johnson & Johnson Description and Business Overview
    Table 38. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Johnson & Johnson (2019-2024)
    Table 40. Johnson & Johnson Recent Developments
    Table 41. Sanofi S.A Basic Information List
    Table 42. Sanofi S.A Description and Business Overview
    Table 43. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Sanofi S.A (2019-2024)
    Table 45. Sanofi S.A Recent Developments
    Table 46. Dendreon Corporation Basic Information List
    Table 47. Dendreon Corporation Description and Business Overview
    Table 48. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Dendreon Corporation (2019-2024)
    Table 50. Dendreon Corporation Recent Developments
    Table 51. Bayer AG Basic Information List
    Table 52. Bayer AG Description and Business Overview
    Table 53. Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Bayer AG (2019-2024)
    Table 55. Bayer AG Recent Developments
    Table 56. Key Raw Materials Lists
    Table 57. Raw Materials Key Suppliers Lists
    Table 58. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Downstream Customers
    Table 59. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Distributors List
    Table 60. Research Programs/Design for This Report
    Table 61. Key Data Information from Secondary Sources
    Table 62. Key Data Information from Primary Sources
    Table 63. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Picture
    Figure 2. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 4. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Report Years Considered
    Figure 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in 2023
    Figure 7. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Oral Therapy Picture
    Figure 9. Injectable Therapy Picture
    Figure 10. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Hospitals & Clinics
    Figure 13. Product Picture of Home Settings
    Figure 14. Product Picture of Ambulatory Surgical Centers (ASCs)
    Figure 15. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value Market Share by Application, 2023 & 2030
    Figure 17. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 18. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 19. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 20. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 21. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 22. Asia Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 23. South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 24. South America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 25. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (2019-2030) & (US$ Million)
    Figure 26. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Country (%), 2023 VS 2030
    Figure 27. Key Countries/Regions Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value (%), (2019-2030)
    Figure 28. United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 29. United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 30. United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 31. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 32. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 33. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 34. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 35. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 36. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 37. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 39. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 40. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 41. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 42. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 43. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 45. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 46. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value, (2019-2030) & (US$ Million)
    Figure 47. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Type (%), 2023 VS 2030
    Figure 48. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Sales Value by Application (%), 2023 VS 2030
    Figure 49. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Industrial Chain
    Figure 50. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Manufacturing Cost Structure
    Figure 51. Channels of Distribution (Direct Sales, and Distribution)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation

Description

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Market Segmentation